MYB is an oncogenic transcription factor that is often aberrantly expressed in hematologic malignancies, mostly in acute myeloid leukemia (AML). Rgenta Therapeutics Inc. recently presented data for RGT-61159, a potent and selective MYB inhibitor compound that demonstrated cell killing across a panel of MYB-overexpressing leukemic cell lines.

Bispecific antibodies mimicking coagulation factor VIIIa (FVIIIa) have yielded successful results in the treatment of hemophilia A, but there remain some issues in regard to their production.

Therapies against aggressive T-cell lymphomas (TCLs) are limited and treatment resistance to histone deacetylase (HDAC) inhibitors often occurs. Polycomb protein EED is a key member of the polycomb repressive complex 2 (PRC2) complex and is an attractive therapeutic target for TCLs. APG-5918 is an EED inhibitor from Ascentage Pharma Group International Co. Ltd. that has been proven to disrupt the PRC2 functioning and has been tested in preclinical TCL models as a promising approach.

At the 2025 Annual Congress of the European Association for Cancer Research (EACR), researchers from Cardiff University and collaborators presented their research on the role of BCL3 in tumor progression and the therapeutic potential of TNAT-101.

In recognition of the fact that diversity, equity and inclusion (DEI) are necessary prerequisites for precision medicine, the European Academy of Neurology (EAN) announced the launch of a DEI Hub at its 11th Congress, which is being held in Helsinki through June 24. “We know now that when we talk about personalized medicine, we have to understand that talking about stroke, for example, in a woman is different than talking about stroke in a man,” EAN president Elena Moro told the audience at the opening session of the conference.

Multiple myeloma bone disease (MBD) lacks effective biomarkers; recent evidence involves exosomal circRNAs in the progression of cancer, but their roles in the field have not been deeply explored. The aim of this study was to explore the role of component of oligomeric golgi complex 5 (COG5) and shed light on its osteolytic mechanism.

Researchers from the National Cancer Institute and their collaborators have presented data regarding a MLK3-degrading PROTAC, CEP1347-VHL-02, for treating triple-negative breast cancer.

At the Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, multiple sessions aimed to provide fresh perspectives on the always challenging treatment of cancer, with a strong focus on innovative strategies.